Teratogenicity and Fetal-Transfer Assessment of the Retinoid X Receptor Agonist Bexarotene.
Journal
ACS pharmacology & translational science
ISSN: 2575-9108
Titre abrégé: ACS Pharmacol Transl Sci
Pays: United States
ID NLM: 101721411
Informations de publication
Date de publication:
09 Sep 2022
09 Sep 2022
Historique:
received:
27
06
2022
entrez:
16
9
2022
pubmed:
17
9
2022
medline:
17
9
2022
Statut:
epublish
Résumé
Bexarotene, a retinoid X receptor (RXR) agonist, is used to treat cutaneous T-cell lymphoma, and drug repositioning research has also been reported, despite warnings of teratogenicity. However, fetal transfer of bexarotene and its effect on rat fetal bone formation have not been examined. In this study, we conducted a detailed teratogenicity and fetal transferability assessment of bexarotene in rats. Repeated administration of bexarotene during pregnancy caused marked fetal atrophy and bone dysplasia. Although fetal transfer was not detectable by dynamic imaging of [
Identifiants
pubmed: 36110376
doi: 10.1021/acsptsci.2c00126
pmc: PMC9469495
doi:
Types de publication
Journal Article
Langues
eng
Pagination
811-818Informations de copyright
© 2022 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare the following competing financial interest(s): This study was also funded in part by AIBIOS K.K. This funder was not involved in the study design, data collection, analysis, interpretation of data, writing of the article or the decision to submit it for publication. All authors declare no other competing interests.
Références
Neoplasia. 2012 Feb;14(2):159-68
pubmed: 22431924
Cell. 1995 May 19;81(4):541-50
pubmed: 7758108
Biochem Pharmacol. 2001 Dec 1;62(11):1501-9
pubmed: 11728386
Cell. 1995 Dec 15;83(6):841-50
pubmed: 8521508
Ann Biomed Eng. 2019 Jan;47(1):1-21
pubmed: 30218224
Nucl Med Biol. 2005 Oct;32(7):673-8
pubmed: 16243641
Pharmacol Res. 2020 Sep;159:104960
pubmed: 32473310
Clin Lymphoma. 2003 Mar;3(4):249-52
pubmed: 12672276
Arch Toxicol. 2005 May;79(5):243-52
pubmed: 15902421
J Med Chem. 2017 Aug 24;60(16):7139-7145
pubmed: 28753292
Nature. 1997 Mar 27;386(6623):407-10
pubmed: 9121558
Teratology. 1995 Apr;51(4):257-65
pubmed: 7570368
ChemMedChem. 2008 May;3(5):780-7
pubmed: 18297677
Adv Biomed Res. 2013 Mar 06;2:19
pubmed: 23930264
Ecotoxicology. 2012 Jul;21(5):1465-75
pubmed: 22526925
Bioorg Med Chem Lett. 2019 Aug 1;29(15):1891-1894
pubmed: 31160175
Blood. 2008 Oct 15;112(8):3082-7
pubmed: 18647960
ACS Omega. 2020 Apr 02;5(14):8242-8250
pubmed: 32309734
J Med Chem. 2021 Apr 22;64(8):5123-5136
pubmed: 33793232
Diabetologia. 1999 May;42(5):545-54
pubmed: 10333046
Science. 2020 Feb 28;367(6481):
pubmed: 32108090
Lancet Neurol. 2012 Sep;11(9):803-13
pubmed: 22805351
J Med Chem. 2019 Feb 28;62(4):2112-2126
pubmed: 30702885
Sci Rep. 2017 Feb 16;7:42270
pubmed: 28205585
ACS Med Chem Lett. 2014 Feb 27;5(6):668-72
pubmed: 24944741
J Med Chem. 1994 Sep 2;37(18):2930-41
pubmed: 8071941
ACS Med Chem Lett. 2015 Jan 20;6(3):334-8
pubmed: 25815156
Methods Mol Biol. 2013;947:383-401
pubmed: 23138918
ACS Chem Neurosci. 2013 Nov 20;4(11):1430-8
pubmed: 24117438
J Med Chem. 2013 Nov 14;56(21):8432-54
pubmed: 24180745
J Med Chem. 2019 May 9;62(9):4780-4781
pubmed: 31002501
Biochem Pharmacol. 1995 Aug 25;50(5):669-76
pubmed: 7669070
Clin Perinatol. 1986 Sep;13(3):545-54
pubmed: 2945687
Immunotherapy. 2013 Apr;5(4):427-33
pubmed: 23557425
Eur J Cancer. 2006 May;42(8):1014-30
pubmed: 16574401